Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct 25;18(1):1-8.
doi: 10.1080/2090598X.2019.1677296. eCollection 2020.

Antibiotic therapy in patients with high prostate-specific antigen: Is it worth considering? A systematic review

Diaa-Eldin Taha  1 , Omar M Aboumarzouk  2   3 , Islam Osama Koraiem  4 , Ahmed A Shokeir  5
Affiliations
Review

Antibiotic therapy in patients with high prostate-specific antigen: Is it worth considering? A systematic review

Diaa-Eldin Taha et al. Arab J Urol. .

Abstract

Objective: To address the question of whether antibiotic therapy can obviate the need for prostate biopsy (PBx) in patients presenting with high prostate-specific antigen (PSA) levels. Methods: With the increase in unnecessary PBx in men with high PSA levels, a systematic review was performed according to the Cochrane Reviews guidelines and in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist. Results: The literature search yielded 42 studies, of which 11 were excluded due to irrelevance of data. Most of the studies were retrospective, nine studies were randomised controlled trials, and there were seven prospective non-randomised trials. The age range of the patients was 51-95 years. Antibiotics, predominantly ofloxacin or ciprofloxacin, combined with a non-steroidal anti-inflammatory drug (NSAID) or not, were prescribed for 2-8 weeks. All studies focussed on PSA levels ranging from ≤ 4 to ≥ 10 ng/mL. Furthermore, antibiotic therapy normalised PSA levels by a wide variety of percentages (16-59%), and the PSA level decrease also varied widely and ranged from 17% to 80%. For patients who had unchanged or decreased PSA, carcinoma was found in 40-52% and 7.7-20.3%, respectively. No cancer was detected if the PSA level decreased to < 4 ng/mL. Conclusion: Antibiotic therapy is clinically beneficial in patients with high PSA levels. PSA reduction or normalisation after medical therapy, either antibiotic and/or NSAID, for ≥ 2 weeks can avoid unnecessary PBx. Antibiotic therapy is more beneficial when the PSA level is < 20 ng/mL. Abbreviations: EPS: expressed prostatic secretion; PBx: prostate biopsy; (%f)(f/t)(t)PSA, (percentage free) (free/total) (total) serum PSA; PSAD: PSA density; RCT: randomised controlled trial; VB3: voided bladder urine 3.

Keywords: Antibiotic therapy; non-steroidal anti-inflammatory drugs (NSAIDs); prostate biopsy (PBx); prostate-specific antigen (PSA).

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flowchart of article selection.
See this image and copyright information in PMC

References

    1. Liu J, Hu WL.. [Can antibiotic treatment exclude inflammation in the differential diagnosis of elevated PSA?] [Article in Chinese]. Zhonghua Nan Ke Xue. 2012;18:747–750. - PubMed
    1. Singh R, Cahill D, Popert R, et al. Repeating the measurement of prostate-specific antigen in symptomatic men can avoid unnecessary prostatic biopsy. BJU Int. 2003;92:932–935. - PubMed
    1. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700. - PMC - PubMed
    1. Azab S, Osama A, Rafaat M. Does normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy? Transl Androl Urol. 2012;1:148–152. - PMC - PubMed
    1. Erol H, Beder N, Calişkan T, et al. Can the effect of antibiotherapy and anti-inflammatory therapy on serum PSA levels discriminate between benign and malign prostatic pathologies? Urol Int. 2006;76:20–26. - PubMed